We are a specialist corporate finance adviser helping private Healthcare and Technology companies Finance Growth and Realise Value
Our Team
Our team is led by Hugh Kingsmill Moore and Phil Walker who bring over 50 years of corporate advisory experience in healthcare and technology between them. They were co-founders of Code Securities, later Nomura Code, one of the most successful specialist advisory businesses in the UK market. Coming together again to create Moore Walker Partners, they are laser-focused on helping smaller/mid-market private healthcare and technology companies finance growth and realise value.
Hugh Kingsmill Moore
Founding Partner
Hugh has spent 28 years raising growth capital and advising on M&A for companies in healthcare and technology sectors. His early career was spent at investment banks (Nomura, ING Barings, RBC, Zeus Capital) in specialist sales roles and leading equity sales teams in public markets. Hugh was a co-founder and Head of Sales at Code Securities, where he led numerous IPOs and secondary fund raises for LSE listed life science and technology companies. Since 2018, Hugh has focussed on private capital markets, working at Alti (formerly Alvarium) as Head of Equity Capital Markets, then spinning out with the merchant banking team in 2023 to form J Goodwin & Co, where he continued is his role of Head of Capital Markets with an increased focus both on healthcare and on M&A advisory work.
Phil Walker
Founding Partner
Phil has over 25 years’ corporate finance and investment banking experience advising entrepreneurs, boards, C-suite executives and shareholders of small to mid-sized high growth healthcare, life sciences and technology-based companies on value creation and realisation and has a track record of deal origination and execution, across IPOs, secondary fundraisings, private placements and M&A. He qualified as a chartered accountant with Price Waterhouse before moving into corporate finance at WestLB Panmure. He went on to co-found start-up boutique investment bank, Code Securities, which grew to become the number 1 rated adviser in European life sciences and was acquired by Nomura. He has subsequently held senior positions as Head of Healthcare & Cleantech at Zeus Capital, Managing Director Healthcare at Bryan Garnier & Co, and Head of Healthcare at Liberum Capital.
Luke Shuttleworth
Analyst
Luke is a highly motivated and analytically driven individual. He holds a First-Class Honours degree in Business and Management from the University of Exeter. With a strong academic foundation built at Cheltenham College and Bishops Diocesan College in Cape Town, he has consistently demonstrated academic excellence and a commitment to personal growth. Since graduating, Luke has worked as an Analyst at Impact Lens in London, a small wealth manager, and has lead research and investment analysis, contributing to start-up funding decisions and the evaluation of Managed Portfolio Solutions. Prior to this, he gained valuable work experience at J Goodwin and Co. Merchant Bank further honing his financial acumen and client-facing skills in high-pressure environments. Luke holds certificates in Financial Modelling & Valuation as well as EIS & SEIS accreditation. Outside of finance, Luke is a passionate sportsman, having represented Gloucester Rugby U18 Academy, Western Province Squash, and enjoys golf, padel, and chess.
Senior Advisers
Charles Spicer
Charles Spicer has over 25 years’ experience as a director, chair and adviser to companies especially in the medtech and life sciences industries. He currently serves as the Chair of EMV Capital Plc, Korn Wall Limited and Cryogenx. He is also a trustee of several charities. He previously chaired Creo Medical Group plc, IXICO plc and a panel for the UK Department of Health's Invention for Innovation (i4i) program. Charles was previously Chief Executive of MDY Healthcare plc, a strategic healthcare investment firm. Prior to that, he served as Head of Healthcare Corporate Finance at Numis Securities and Nomura International. Charles holds a PhD from London University and an MA from Cambridge University, both in History.
Roy Davis
Roy is an experienced executive with over 35 years of global experience in a variety of industries including medtech, diagnostics and technology sectors. He is currently Chairman of Inspiration Healthcare Group plc, a leading neonatal respiratory company and Foster & Freeman Ltd (the trading name of the Galton group of companies), a leading forensic imaging manufacturer. He is also a Non-Executive Director of Futura Medical plc, a UK pharmaceutical company focussed on the sexual health market and Chairman of LunglifeAI Inc. a lung cancer diagnostics company. Roy was previously Chairman of Medica Group plc until its sale to IK Partners in 2023 and Chairman of Edinburgh Molecular Imaging Ltd and RAIR Health Ltd. Before these Non-Executive roles Roy served as the Chief Executive Officer of Optos plc, a leading ophthalmology medical device business, from 2008 until June 2016 when he stepped down following the company’s acquisition by Nikon Corporation. Before joining Optos, he served from 2007 as Chief Executive Officer of Gyrus Group plc, a leading medical device company, prior to its acquisition by the Olympus Corporation of Japan in 2008, having previously served as Chief Operating Officer of Gyrus from 2003 and a non-executive director since flotation in 1997. Roy holds a mechanical engineering degree from the University of Southampton and an MBA from the London Business School.
Juliet Thompson
Juliet has over 30 years of finance, banking and board experience with significant focus in the healthcare sector. She is a proven FTSE 250 audit chair and a former investment banker who has spent her career advising pharmaceutical companies. She played a leading role in setting up Code Securities, which was later acquired by Nomura (becoming Nomura Code) but remained independent. At Nomura Code, Juliet was advising companies in the healthcare and clean tech sectors on their financing and strategic options. She worked on over 50 transactions including IPOs, secondary offerings, private placements and M&A. As Nomura Code was devolved, she joined Stifel with a team from Nomura Code to head up the life sciences and clean tech teams where she advised CEOs and CFOs in the healthcare sector. Since retiring, Juliet has built a diverse portfolio; she is currently a Non-Executive Director and Chair of the Audit Committees of Indivior plc, Novacyt S.A. and Organox Limited. She previously served on the Board of GI Dynamics Inc. and Angle PLC. Juliet holds a BSc in Economics from the University of Bristol and qualified as a Chartered Accountant and holds an ACA from the Association of Chartered Certified Accountants.
Joanna Smart
Jo is a respected life sciences NXC, CEO, investor, NED and chair of UK government health innovation funding streams. She has over 25 years’ experience in the sector, most recently as investor with BGF’s early stage life sciences portfolio. Prior to BGF, Jo was Non-Executive Chair of Oxford Cancer Biomarkers, a commercial stage cancer diagnostics business, and was previously CEO of UK female health medtech Verso Biosense, building the company from academic start-up to clinical-stage SME. She has led corporate development and M&A both as operator and adviser for public and private life sciences companies in the UK and US and is currently Chair of the National Institute for Health Research (NIHR) i4i Product Development Awards Panel.
Contact us
Hugh Kingsmill Moore
email: hugh@moorewalkerpartners.com
mobile: +44 (0) 7776 135 077
Phil Walker
email: phil@moorewalkerpartners.com
mobile: +44 (0) 7880 788 392
Moore Walker Partners Ltd is authorised and regulated by the Financial Conduct Authority, FRN 1055066
Registered in England & Wales, company no: 16479455
Registered office address: Scotlands House, Forest Road, Warfield, Berkshire, United Kingdom, RG42 6AJ
VAT registration number: 512711626
